Overview
LXRA Gene Polymorphisms and Response to Fenofibrate
Status:
Terminated
Terminated
Trial end date:
2009-08-01
2009-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a research study of how a cholesterol medication known as fenofibrate works differently in people with different genetic backgrounds. "Genetics" refers to certain things that are passed to a person by their parents, such as eye color or hair color. Genetic differences lead to people having different eye and hair color. There are also genetic differences in a protein called liver X receptor-alpha (LXRA), which may be important in predicting the response to fenofibrate.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
University of FloridaCollaborator:
American College of Clinical PharmacyTreatments:
Fenofibrate
Criteria
Inclusion Criteria:- Triglycerides equal to or above 150mg/dL or Low HDL (below 44 mg/dl for men or below
54 mg/dl for women)
- Must be able to swallow tablets
Exclusion Criteria:
- Known Coronary Heart Disease, symptomatic carotid artery disease, abdominal aortic
aneurysm, diabetes, or Framingham risk score above 20%
- Pregnancy, malignancy, liver dysfunction, renal dysfunction, active alcohol abuse,
history of unexplained muscle pain
- Current treatment with lipid lowering therapy, estrogens, androgens, progestins,
thiazide diuretics, beta-blockers, glucocorticoids (other than inhaled),
antihistamines, or chronic anti-inflammatory drugs
- Current treatment with the following the interacting drugs: ursodeoxycholic acid,
ursodiol, cholestyramine, red yeast rice, glyburide, glipizide, warfarin, or
cyclosporine